Citizen Petition Process Needs Reforming, FDA Chief Counsel Says

Drug Industry Daily
KEYWORDS FDA / NDA
A A

The FDA’s chief counsel wants to reform the citizen petition process to discourage brand drugmakers from filing petitions simply to delay generic drug debuts.

To View This Article:

Login

Subscribe To Drug Industry Daily